Cargando…

Ipatasertib exhibits anti-tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer in vitro and in vivo

Endometrial cancer is the most common gynecologic cancer and one of the only cancers for which incidence and mortality is steadily increasing. Although curable with surgery in the early stages, endometrial cancer presents a significant clinical challenge in the metastatic and recurrent setting with...

Descripción completa

Detalles Bibliográficos
Autores principales:	O'donnell, Jillian, Zhao, Ziyi, Buckingham, Lindsey, Hao, Tianran, Suo, Hongyan, Zhang, Xin, Fan, Yali, John, Catherine, Deng, Boer, Shen, Xiaochang, Sun, Wenchuan, Secord, Angeles Alvarez, Zhou, Chunxiao, Bae-Jump, Victoria L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552741/ https://www.ncbi.nlm.nih.gov/pubmed/37503790 http://dx.doi.org/10.3892/ijo.2023.5551

Ejemplares similares

Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma
por: Burkett, Wesley C., et al.
Publicado: (2023)

Asparagus officinalis combined with paclitaxel exhibited synergistic anti-tumor activity in paclitaxel-sensitive and -resistant ovarian cancer cells
por: Zhang, Xin, et al.
Publicado: (2022)

Orlistat exerts anti-obesity and anti-tumorigenic effects in a transgenic mouse model of endometrial cancer
por: Xu, Guangxu, et al.
Publicado: (2023)

Oleic Acid Exhibits Anti-Proliferative and Anti-Invasive Activities via the PTEN/AKT/mTOR Pathway in Endometrial Cancer
por: Deng, Boer, et al.
Publicado: (2023)

Inhibition of CDK1 by RO-3306 Exhibits Anti-Tumorigenic Effects in Ovarian Cancer Cells and a Transgenic Mouse Model of Ovarian Cancer
por: Huang, Yu, et al.
Publicado: (2023)

A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer
por: Paraghamian, Sarah E., et al.
Publicado: (2023)

Asparagus officinalis Exhibits Anti-Tumorigenic and Anti-Metastatic Effects in Ovarian Cancer
por: Xu, Guangxu, et al.
Publicado: (2021)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
por: Shi, Zhen, et al.
Publicado: (2022)

Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer
por: Pierce, Stuart R., et al.
Publicado: (2021)

Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications
por: Sutaria, Dhruvitkumar S., et al.
Publicado: (2022)

Phenformin has anti-tumorigenic effects in human ovarian cancer cells and in an orthotopic mouse model of serous ovarian cancer
por: Jackson, Amanda L., et al.
Publicado: (2017)

Pharmacokinetics of Ipatasertib in Subjects With Hepatic Impairment Using 2 Methods of Classification of Hepatic Function
por: Sane, Rucha, et al.
Publicado: (2021)

ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro
por: Zhang, Yingao, et al.
Publicado: (2020)

Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells
por: Laterza, Maria Maddalena, et al.
Publicado: (2021)

Exposure–Response‐Based Product Profile–Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer
por: Zhu, Rui, et al.
Publicado: (2019)

Characterization of exposure–response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study
por: Kotani, Naoki, et al.
Publicado: (2022)

Biological role of matrix stiffness in tumor growth and treatment
por: Deng, Boer, et al.
Publicado: (2022)

The Effects of NT-1044, a Novel AMPK Activator, on Endometrial Cancer Cell Proliferation, Apoptosis, Cell Stress and In Vivo Tumor Growth
por: Roque, Dario R., et al.
Publicado: (2021)

Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer
por: Sutaria, Dhruvitkumar S., et al.
Publicado: (2022)

CTCF genetic alterations in endometrial carcinoma are pro-tumorigenic
por: Marshall, A D, et al.
Publicado: (2017)

Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2019)

The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer
por: Stine, Jessica E., et al.
Publicado: (2015)

Analysis of in vitro chemoresponse assays in endometrioid endometrial adenocarcinoma: an observational ancillary analysis
por: Davidson, Brittany A., et al.
Publicado: (2016)

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial
por: Turner, Nicholas, et al.
Publicado: (2021)

Tumor grade and chemotherapy response in endometrioid endometrial cancer
por: Davidson, Brittany A., et al.
Publicado: (2016)

Molecular Classification to Prognosticate Response in Medically Managed Endometrial Cancers and Endometrial Intraepithelial Neoplasia
por: Puechl, Allison M., et al.
Publicado: (2021)

Suppressed tumorigenicity of human endometrial cancer cells by the restored expression of the DCC gene
por: Kato, H, et al.
Publicado: (2000)

Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis
por: Sun, Li, et al.
Publicado: (2018)

Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model
por: Jing, Jing, et al.
Publicado: (2022)

Performance of sentinel lymph node biopsy in high-risk endometrial cancer
por: Ehrisman, Jessie, et al.
Publicado: (2016)

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells
por: Morgillo, Floriana, et al.
Publicado: (2017)

Lumbee Native American ancestry and the incidence of aggressive histologic subtypes of endometrial cancer
por: Zhang, Chelsea, et al.
Publicado: (2015)

Disparities in the surgical staging of high-grade endometrial cancer in the United States
por: Foote, Jonathan R., et al.
Publicado: (2017)

Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells
por: Friel, Anne M, et al.
Publicado: (2010)

ALKBH5 regulates IGF1R expression to promote the Proliferation and Tumorigenicity of Endometrial Cancer
por: Pu, Xiaowen, et al.
Publicado: (2020)

LINC00665 enhances tumorigenicity of endometrial carcinoma by interacting with high mobility group AT-hook 1
por: Cai, Yixuan, et al.
Publicado: (2021)

Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells
por: Han, Xiaoyun, et al.
Publicado: (2015)

Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer
por: Chandra, Vishal, et al.
Publicado: (2021)

RF22 | PMON05 Parabens Promote Pro-Tumorigenic Effects in Luminal Breast Cancer Cell Lines With Diverse Genetic Ancestry
por: Trevino, Lindsey, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hfld2gcdkf35vvr975rs8saohr